Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
We ll get the updates we are waiting for this week.
The company is well aware of the disruption vaccines news have caused within pharma stocks and they also know that within days more approvals will come along.
It would be plausible that SNG, their brokers and advisors have presumably worked out a strategy to come out of this sh*t.
That is realeasing updates or relevant news at the right time in order to change the current scenario.
Imo the most promising covid stocks, SNG is one, should gain momemtum again soon, with or without any vaccines news along the way.
Media coverage will follow and both vaccines and treatments will get their share of the market.
Soon we ll know.
My avg is 95 15/20% down altough still have old free shares in my stock&share account.
Let's see how this plays out.
Sng is very tight on updating the market and RM said the next significant news realease would have been re the home trial.
No idea if they can realease preliminary interim results about the home trial half way through without having dosed the last patient?
However I presume that even of they have started already p3 without releasing an rns they should inform SH when first patient is enrolled and trigger some reaction.
A catalyst coming from the media would do the same.
ATB
@troajan
From you history I can see you have knowledge when it comes to market. Are you day trading SNG?
What's your view in the short and medium term on this share?
Imo looking at charts, can see weakness, strong downtrend, 20ma below 200ma ( 50 though still above 200) not many buying signals etc with chance for sp to go lower at 72 esistance or tested again.
Unless we get some good news and a quick change in sentiment and a rerate.
I know pharma company can be unpredictable, a bounce back here is overdue despite the technicals.
I wonder why stocks as tils have been so often priced the same as SNG, it seems they trade pari passu even though they have different drugs in their portfolio etc.
Whats your view?
Thanks
ATB
@pharma123 quick message before i filter you
RM never said P3 to start in november. He said Q4 read rns.
In the last webinar he said cpls of weeks. It was the 18th November.
In the 30th nobember webinar also confirmed as starting imminently.
And results will be out, at least the interim preliminary ones within first half of Q1 2021 as RM stated.
EUA approval will be granted if and when more data will be available, that's what phase 3 is for. As said more than one time n the last webinar.
Stop talking nonsense if you are unhappy sell and stop posting crap.
I have emailed Sky and BBC
Dear Sir/Madam
Dear Sky News Team
I am writing to you in order to rise some awareness and express my disappointment in regards with the recent general media coverage about Covid-19 treatments.
Currently and mostly since the beginning of the pandemic, the majority of the UK Media channels have primarily focused only on vaccines and have, apart from some brief reports earlier this year seemingly forgotten about the treatments and therapeutic side of the matter in terms of new developments and progression made since the end of the summer.
In particular, I would like to bring to your attention Synairgen Ltd, which you have covered in your reports in April.
Based in Southampton and founded from an extremely experienced team, including the recently Knighted Prof Stephen Holgate, this company have made substantial progress in the fight against Covid-19 with their inhaled interferon beta drug SNG001.
They have now started a global phase 3 trial in 26 countries including UK, USA, Central and South America, whole Europe, South Africa and more.
Their previous phase 2 trial results, which have been already published in the Lancet Journal, have shown a 79% lower risk for patients of developing severe disease compared to the placebo arm being twice as likely to recover from Covid-19 as those on placebo.
This is a great English story from a UK Biotech and Research company which have been forgotten from the media.
This is in my opinion disappointing given the fact that the only reports the public can hear of are about vaccines vaccines and vaccines.
I appreciate the importance for the coverage in regards to vaccines and the need for immunisation in order to get through this unprecedented time, nevertheless therapeutics are also part of the puzzle both in the short and the long term.
They are equally relevant and must be taken into account from both media and government.
SNG001 is a broad spectrum antiviral which have been studied for almost fifteen years and have shown high efficacy in COPD, Asthma, Influenza like viruses and other viral pulmonary conditions.
Hence, if data from this fast tracked phase 3 trail would show the same efficacy as previously such drug could very well be a breakthrough drug as it has already demonstrated, for fighting the pandemic, save lives, protect the elderly and play a major role for the above mentioned medical conditions.
In conclusion, I would be pleased to see more extensive media coverage for treatments and therapeutics and the progress that UK science have made in studying Covid-19, particularly Synairgen with their inhaled version on Interferon Beta SNG001.
A Great UK story.
Yours Faithfully,
"Covid vaccine trials did NOT monitor whether participants took other steps to prevent infection like wearing masks and social distancing".
https://www.google.com/amp/s/www.dailymail.co.uk/health/article-8990763/amp/Covid-vaccine-trials-did-not-monitor-participants-wore-masks-socially-distanced.html
Immunizations are speeding towards approval before clinical trials end, but scientists say this could complicate efforts to study long-term effects.
Worth a read.
https://www.nature.com/articles/d41586-020-03219-y
@beforegolf
If you go for UK Europe and US stocks it will cost you around 600£ per year. Take Europe off and you pay slightly less.
The price depends on which stocks you choose globally.
Lots of info research and fundamentals explained in every stock.
Descret stock scanner which they always aim to improve.
Same for charting.
Considering that you could pay up to 2k alone for a powerful customized stock scanner, Stockopedia could well be a cheaper but still very good option.
..if you are willing to spend that money.
ATB
"Building a strong relationship with the FDA is essential for a successful drug program. This begins with taking advantage of the valuable information that can be gleaned from pre-IND meetings. Proper utilization of pre-IND meetings may reduce the drug’s time to market and ensure that the proposed studies are designed to provide useful information"
https://www.oraclinical.com/resource/the-basics-of-a-pre-ind-meeting/
The way I see it is that
We will have confirmation of p3 start and details shortly
We will then before Xmas have the interim preliminary results for the home trial
And following that finally recieve EUA
P3 would as a result be a very fast trial with first read out by end of January.
In an ideal world!
Hi Chris
I have done the same maths as you have but no rns.
This time I didnt include weekend? I dont know if is the case or not. Not sure if it's 30 days including weekends or not.
I think is the latter.
Very likely we receive an announcement in regards next week.
Hope so!
ATB
If the IND application has been filed October 19th, on Monday after placing rns (not including weekends) tomorrow will be 30 days since the apllication was made.
Considering it is Thanksgiving in the USA, next week we could have the announcement we have all been waiting for.